PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A...

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Advanced non-small-cell lung cancer (NSCLC) remains a significant clinical challenge.
• The combination of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors with chemotherapy is a novel therapeutic strategy.
• Evaluating the efficacy of this combined approach is crucial for optimizing treatment for advanced NSCLC.

Purpose of the Study:

• To conduct a meta-analysis evaluating the efficacy of PD-(L)1 inhibitors combined with chemotherapy versus chemotherapy alone in advanced NSCLC.
• To assess the impact of this combination therapy on progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).
• To analyze treatment benefits across various patient subgroups, including those stratified by PD-L1 expression.

Main Methods:

• A systematic literature search was performed to identify randomized controlled trials.
• Included trials compared PD-(L)1 inhibitors plus platinum-based chemotherapy against chemotherapy alone in stage IV NSCLC patients.
• Data from seven trials involving 4562 patients were analyzed.

Main Results:

• The combination of PD-(L)1 inhibitors and chemotherapy significantly improved PFS (HR=0.61) and OS (HR=0.76) in the intention-to-treat wildtype population.
• A significantly higher ORR (OR=2.12) was observed with the combined strategy compared to chemotherapy alone.
• Benefits were consistent across analyzed subgroups, irrespective of PD-L1 expression status.

Conclusions:

• Adding PD-(L)1 blockade to standard platinum-based chemotherapy significantly enhances PFS, OS, and ORR in the upfront treatment of advanced NSCLC.
• This combination therapy represents a promising and effective treatment option for patients with advanced NSCLC.
• The findings support the use of PD-(L)1 inhibitors in combination with chemotherapy for improved patient outcomes.